MYD88 and neoplasm: TgPLP plays an auxiliary role in the treatment of autologous whole-tumor-cell vaccine by activating the MyD88 pathway, resulting in an increase in the level of antigen-presenting cell markers in bone marrow-derived macrophages, which increases the production of IL-12 and promotes their phagocytosis of tumor cells (Pyo et al., 2016).